H727 cells are inherently resistant to the proteasome inhibitor carfilzomib, yet require proteasome activity for cell survival and growth

Min Jae Lee1, Zachary Miller1, Ji Eun Park2, Deepak Bhattachari, Wooin Lee2, & Kyung Bo Kim1

The second-in-class proteasome inhibitor (PI) carfilzomib (Kyprolis, Cfz) has contributed to a substantial advancement in multiple myeloma treatment by improving patient survival and quality of life. A considerable portion of patients however display intrinsic resistance to Cfz. Our mechanistic understanding of intrinsic Cfz resistance is limited due to a lack of suitable cell-based models. We report that H727 human bronchial carcinoid cells are inherently resistant to Cfz, yet susceptible to other PIs and inhibitors targeting upstream components of the ubiquitin-proteasome system (UPS). These results indicate that H727 cells remain dependent on the UPS for cell survival and growth despite harboring intrinsic resistance to Cfz. Alterations in the composition of proteasome catalytic subunits via interferon-γ treatment or siRNA knockdown results in sensitization of H727 cells to Cfz. We postulate that a potential link may exist between the composition of proteasome catalytic subunits and the cellular response to Cfz. Overall, H727 cells may serve as a useful cell-based model for de novo Cfz resistance and our results suggest previously unexplored mechanisms of de novo PI resistance.

The proteasome, an evolutionarily conserved multiprotease complex, is responsible for the controlled degradation of intracellular proteins. These include defective ribosomal products (DRiPs), oxidized proteins, and tightly-regulated cellular signaling proteins involved in cell cycle progression, immune response, apoptosis, signal transduction, and stress responses. Proteins are targeted for proteasomal degradation by ubiquitination, a process involving a cascade of enzymes: E1 (ubiquitin activating enzyme), E2 (ubiquitin conjugating enzyme), and E3 (ubiquitin ligase). Once protein substrates are polyubiquitinated, they are recognized by the proteasome's regulatory particle (19S complex) and degraded within the central chamber of the core particle (20S complex) of the proteasome. The 20S proteasome core is composed of four stacked heptameric rings: two outer α-rings and two inner β-rings. In mammalian proteasomes, each β-ring harbors three catalytic β-subunits, β1, β2, and β5 which display different substrate preferences, respectively referred to as caspase-like (C-L), trypsin-like (T-L) and chymotrypsin-like (CT-L) activities. It was generally thought that 20S proteasomes exist in two main types, namely, the constitutive proteasome (cP) and the immunoproteasome (iP). Immunoproteasomes differ from cP by the replacement of β1, β2, and β5 with the homologous catalytic subunits β1i, β2i, and β5i. Interestingly, recent investigations revealed that certain tissues and some cancer cells carry non-standard types of 20S proteasomes (referred to as hybrid or intermediate proteasomes), which contain mixed assortments of cP and iP catalytic subunits, such as β1i-β2-β5i. It was further reported that these non-standard proteasomes may confer differing sensitivities to proteasome inhibitors (PIs) as compared to cPs or iP PIs, but the clinical implications of these non-standard proteasomes remain unknown.

The proteasome is an effective anticancer target, validated by the clinical success of the FDA approved proteasome inhibitors (PIs) bortezomib (Velcade, Btz), carfilzomib (Kyprolis, Cfz), and ixazomib (Ninlaro, Ixz) as multiple myeloma (MM) therapies. PIs have become an integral part of MM treatment and have contributed to a major uplift of patient outcomes over the past decade and a half. While the first-in-class PI drug Btz and the first oral PI Ixz utilize boronic acid pharmacophores, the second-generation PI Cfz harbors an epoxyketone that irreversibly inactivates the proteasome with high mechanistic selectivity. This selectivity affords Cfz a reduction...
in off-target interactions yielding an improved safety profile over Btz, most notably a reduced incidence of severe peripheral neuropathy\textsuperscript{10}. With positive results from recent phase III clinical trials\textsuperscript{11–16}, Cfz is now firmly placed as a mainstay of refractory MM therapy. Nevertheless, a considerable portion of MM patients are refractory to Cfz or develop resistance after prolonged Cfz treatment. A meta-analysis of 14 clinical trials found that 44% of patients could not achieve a minimal response or better\textsuperscript{17}. As a monotherapy in patients with relapsed MM, for example, the response rates for Cfz were in the ranges of 25–40%\textsuperscript{18}. When used in combination with other drugs (often with dexamethasone and/or lenalidomide), response rates substantially improved, but a significant subset of non-responders persisted\textsuperscript{16,19–22}. Even for those who initially respond to Cfz-based therapy, disease eventually relapses with a median progression-free-survival (PFS) of ~17–26 months\textsuperscript{20,21}. To date, considerable efforts have been put forth toward the development of new therapeutics for these Cfz non-responders without significant progress. Efforts to tackle this problem have been significantly hampered by a limited understanding of the biological mechanisms underlying Cfz resistance.

Mechanistic investigations of Cfz resistance have so far utilized cancer cell lines adapted to gradually increasing concentrations of Cfz, revealing that the overexpression of P-glycoprotein (P-gp) and mutations or amplification/overexpression of proteasome catalytic subunits are largely responsible for acquired Cfz resistance observed in established cell lines\textsuperscript{23–25}. To date, cell-based models of de novo Cfz resistance are unavailable. Here, we report for the first time that H727 cells (derived from a human bronchial carcinoid tumor) are inherently resistant to Cfz, yet remain dependent on the proteasome for their survival and growth. Our current results suggest that de novo Cfz resistance observed in H727 cells may be mediated at the 20S proteasome level, providing previously unknown insights into the mechanisms of de novo PI resistance.

**Results**

**H727 cells are inherently resistant to Cfz.** When the IC\textsubscript{50} values for Cfz were assessed in a panel of 21 human cancer cell lines derived from various types of cancer, H727 lung cancer cells were most resistant to Cfz, with an IC\textsubscript{50} value of 610 nM (Fig. 1a). Even in the presence of 250 nM of Cfz which usually induces >95% loss of viability in other cancer cell lines, H727 cells survived and grew normally (Fig. 1b; the relative cell viability on day 3 was 88.1% based on the counting of cells not stained with trypan blue dye (Sigma-Aldrich, St. Louis, MO)). While the mechanisms of intrinsic resistance to Cfz has not been reported to date, several studies have shown that P-gp can contribute to acquired resistance to Cfz observed in cancer cell line models and clinical samples from patients with prior Cfz therapy\textsuperscript{24,26,27}. To test whether P-gp plays a role in the de novo Cfz resistance of H727 cells, we performed immunoblotting analysis but found no detectable P-gp expression (Fig. 1c).
Furthermore, treatment of H727 cells with reversin 121, a dipeptide P-gp inhibitor, did not significantly impact the IC50 value of Cfz (Fig. 1d), confirming a P-gp-independent mechanism of resistance. Direct sequencing analyses also indicated that the PSMB5 (encoding β5) and PSMB8 (encoding β5i) genes in H727 cells harbor no mutations (Supplementary Fig. S1). Next, we examined the possibility that Cfz may undergo rapid metabolic inactivation in H727 cells. We treated H727 and H23 (Cfz-sensitive) cells with 500 nM Cfz and collected culture media to measure the levels of remaining Cfz at 6 or 24 h post-treatment. The level of remaining drug was overall comparable between H727 and H23 cells although a slight difference was noted at 24 h (Fig. 1e). We attempted to compare the intracellular drug levels by quantifying the remaining drug levels in lysates of H727 and H23 cells, but the levels were below the lower limit of quantitation (<5 nM) of our current analytical assay. Although it was not feasible to assess the intracellular drug levels, H727 cells contained Cfz in the culture media at the level comparable to or slightly higher than H23 cells. Assuming that Cfz primarily enters cells via passive diffusion (no report yet supporting the presence of uptake transporters for Cfz as far as we know), it appears unlikely that H727 cells have intracellular Cfz levels much lower than H23 cells. Taken together, de novo resistance of H727 cells was not explained by previously reported mechanisms such as P-gp upregulation, genetic mutations in proteasome catalytic subunits, or enhanced metabolic inactivation of Cfz.

The UPS/proteasome remains essential for the survival of H727 cells. Cfz selectively inhibits the proteasome by covalently modifying the N-terminal catalytic threonine residues of 20S proteasome catalytic subunits at nanomolar concentrations while not inhibiting other proteases at concentrations as high as 50 μM.28,29. We thus considered whether H727 cells might have adaptations to endure reduced levels of 20S proteasome function, for example, the use of non-proteasomal protein degradation pathways thus reducing proteasome load. In order to determine whether the 20S proteasome is essential for the survival and growth of H727 cells as it is in Cfz-sensitive cell lines such as H23, we first transfected cells with siRNAs targeting the proteasome α7 subunit to block 20S proteasome assembly (Fig. 2a,b).30,31 After 3 days post-transfection, we observed nearly complete cell death for both H727 and H23 cells (Fig. 2b). The extent and time-course of cell death incurred by α7 knockdown was comparable between H727 and H23 cells, indicating that H727 cells are highly dependent on the 20S proteasome. These results suggested that H727 cells may still respond to proteasome inhibitors other than Cfz. In order to examine this, we treated H727 cells with alternative PIs, particularly ones with differing pharmacophores or structures, such as Btz (a peptide boronic acid) and MG-132 (a peptide aldehyde). These PIs were indeed highly
effective in killing H727 cells and their IC₅₀ values were comparable between H727 and H23 cells (Fig. 2c). We also used two inhibitors targeting non-proteasomal UPS components: PYR-41, an inhibitor of ubiquitin E1 ligase and several DUBs, and P5091, a specific USP7/USP47 inhibitor. Both PYR-41 and P5091 were cytotoxic in H727 and H23 cells with comparable potencies (Fig. 2c). These results further support that H727 cells remain dependent on the ubiquitin-proteasome system, despite their de novo resistance to Cfz.

H727 cells have a distinct composition of proteasome catalytic subunits. To account for the sensitivity of H727 cells to other PIs, we hypothesized whether the subunit composition at the 20S proteasome level may contribute to de novo resistance of H727 cells to Cfz. To test this hypothesis, we compared the proteasome catalytic subunit expression and activity profiles of H727 and H23 cells via immunoblotting analysis and kinetics assays using fluorogenic substrates for individual subunits (β₁, β₂, β₅, β₁i, β₂i, β₅i). In the case of the β₂ and β₂i subunits, their combined trypsin-like activity was assessed due to the lack of a specific fluorogenic substrate that can distinguish the two subunits. As shown in Fig. 3a, the expression pattern of proteasome catalytic subunits in H727 cells differed from that in H23 cells. H727 cells expressed high levels of β₁, β₂, and β₅i, while β₁i expression was undetectable. The expression profile of catalytic subunits in H727 cells was not consistent with those typically expected for the two main 20S proteasome subtypes, namely a set of β₁-β₂-β₅ for cP or an immuno-subunit set of β₁i-β₂i-β₅i for iP. Substantial differences were also noted when the activity profiles of proteasome catalytic subunits were compared between these two cell lines using subunit-selective fluorogenic substrates (Fig. 3b, the relative hydrolysis rates for each probe substrate shown as a heat map and numbers). Interestingly, the activity profiles of individual catalytic subunits showed discrepancies with the protein levels of the respective catalytic subunits. We suspect that the observed differences may reflect the complex relationship between proteasome structure and function (e.g. contributions of post-translational modifications, regulatory particles, or non-standard composition of proteasome catalytic subunits to the hydrolysis rates of fluorogenic substrates).

We next examined whether individual subunits of proteasomes in H727 cells may display different proteasome inhibition profiles than those of H23 cells. We treated H727 and H23 cells with 20 nM of Cfz for 4 h and measured the remaining activities of individual catalytic subunits relative to vehicle-treated control cells. As shown in Fig. 3c (left panel), more than 80% of β₅, β₅i and β₁i activities were blocked by Cfz for both H727 and H23...
cells. On the contrary, over 50% of β1 activity persisted in H727 cells, but not in H23 cells (Fig. 3c, left panel). It remains unclear whether the remaining β1 activity contributes to de novo resistance of H727 cells to Cfz. On the other hand, Btz treatment resulted in over 80% inhibition across all catalytic subunits in both H727 and H23 cell lines, which may explain the high sensitivity of both cell lines to Btz (Fig. 3c, right panel). These results support that the 20S proteasomes present in H727 cells may be functionally different from those in Cfz-sensitive H23 cells.

Upregulation of β1i and β5i levels by IFN-γ sensitizes H727 cells to Cfz. Based on the differential expression pattern of proteasome catalytic subunits in H727 as compared to H23, we hypothesized that the composition of proteasome catalytic subunits may impact the sensitivity of H727 cells to Cfz. To test this hypothesis, we altered catalytic subunit composition in H727 using interferon-γ (IFN-γ) treatment. IFN-γ’s ability to upregulate immuno-subunits (β1i, β2i, and β5i) and to induce IP formation has been well-documented34–38. As shown in Fig. 4a, incubation of H727 cells with IFN-γ (150 U ⋅ ml⁻¹) 24 h prior to Cfz treatment resulted in upregulation of immuno-subunit expression and corresponding increases in their activity. IFN-γ pre-treatment caused a significant decrease in Cfz IC₅₀ values from 621.1 to 189.5 nM in H727 cells. When H23 cells were pre-treated with IFN-γ, the Cfz IC₅₀ values changed in the opposite direction (IC₅₀ values increased from 18.6 to 44.1 nM, Fig. 4b). With IFN-γ pre-treatment, the fold differences in IC₅₀ values between the two cell lines were reduced from 33-fold to 4.2-fold.

Alteration of proteasome catalytic subunit composition affects H727 Cfz sensitivity. In order to further investigate a causal relationship between the composition of proteasome catalytic subunits and Cfz sensitivity, we sought to alter the composition of proteasome catalytic subunits in H727 cells in a more selective manner using an siRNA pool targeting the abundantly expressed β5 subunit. We expected that β5i will substitute for β5 during proteasome assembly, forming 20S complexes with altered catalytic subunit composition. When β5 was knocked down (verified via immunoblotting and activity assays, Fig. 5a,b), H727 cells grew normally with modest upregulation of β5i. Despite their normal growth, H727 cells were significantly sensitized to Cfz by β5 knockdown, shifting the IC₅₀ value from 622 to 99.9 nM (Fig. 5c). In contrast, the IC₅₀ for Btz was only modestly affected, decreasing from 26 to 12 nM (Supplementary Fig. S3). Knockdown of other catalytic subunits such as β3i and β2 resulted in minimal changes in the IC₅₀ values for Cfz. A similar pattern was observed in H23 cells where knockdown of β3i and β2 had little effect on Cfz sensitivity but β5 knockdown triggered a five-fold reduction in Cfz IC₅₀ from 26.7 to 5.0 nM (Fig. 5c).

Inter-patient variability in the proteasome activity profiles of primary MM cells is high. In order to assess whether the observed variability in proteasome activity profiles in PI-naïve cell line models reflects the Cfz sensitivity of clinical MM samples, we examined the proteasome activity profiles and degree of Cfz sensitivity using 6 MM samples from patients who have received no prior PI therapy. Similar to the results obtained using cell line models, the clinical samples also showed considerable variability in catalytic subunit activity profiles and Cfz sensitivity (Fig. 5d). Due to the limited sample quantities, we were not able to perform any further investigations on these samples. Based on these initial assessment, we cautiously speculate that differential Cfz sensitivity in these patient samples may be influenced by variability in proteasome catalytic subunit composition, perhaps partially accounting for the varied responses to Cfz observed in clinical trial results11,15,20.

Figure 4. Effect of IFN-γ pretreatment on carfilzomib sensitivity of H727 (a) and H23 (b) cells. IFN-γ (150 U ⋅ ml⁻¹) pretreatment for 24 h led to increased expression (left panel) and activity (middle panel) of proteasome immuno-subunits, and sensitized H727 cells to Cfz, while desensitizing H23 cells towards Cfz. The IC₅₀ values displayed a statistically significant difference between IFN-γ-pretreated cells and vehicle control (P value < 0.01, n = 3, Student’s t-test comparing the log transformed IC₅₀ values obtained from three independent runs).
Discussion

The advent of Cfz therapy has improved outcomes for many MM patients. However, like many other anticancer agents, the successful clinical use of Cfz is significantly challenged by the presence of intrinsic and acquired drug resistance. A significant fraction of MM patients previously treated with Btz-containing regimens do not respond to Cfz and even those who initially respond to Cfz almost invariably develop resistance in the course of their treatment11,17,39. In order to design new and effective therapeutic strategies which avoid, eliminate, or bypass resistance, it is important to better understand the mechanisms of Cfz resistance. To date, investigations of Cfz resistance have largely focused on acquired resistance due to the relative ease of generating Cfz-adapted cancer cell lines and the availability of clinical samples derived from patients who have developed resistance after prolonged Cfz therapy. On the other hand, mechanistic investigations of de novo Cfz resistance have been scarce, due to the lack of appropriate cell line models and patient samples. In the current study, we report that H727 cells are intrinsically resistant to Cfz, potentially serving as a useful model for mechanistic investigations of de novo Cfz resistance. Given that H727 cells were sensitive to inhibitors of non-proteasomal targets in the UPS and PIs other than Cfz, we surmise that H727 cells harbor functionally active proteasomes and that complete or near-complete inhibition of proteasome catalytic activity is incompatible with survival in these cells. Based on our current results, a shift towards non-UPS protein degradation pathways appears unlikely since H727 cells remain highly sensitive to the inhibition of UPS components including the proteasome itself.

Despite their similar degrees of dependence on the proteasome or UPS for survival and growth, H727 and H23 cells respond differently to Cfz, to a degree of 33-fold difference in IC$_{50}$ values. This may be in part due to cell line-dependent cell growth rates or genetic/molecular differences. However, the high sensitivity of H727 cells to other PIs suggests that Cfz resistance in H727 cells may be mediated at the 20S proteasome level. It has been reported that proteasome inhibitor resistance is often associated with increased levels of proteasome subunit catalytic activity, especially in models of acquired bortezomib resistance30,41. However, H727 cells displayed substantially low activities of individual catalytic subunits as compared to H23 cells. At present, it is unclear whether the low proteasome activities in H727 cells are involved in conferring Cfz resistance. Previously it was reported that 20S proteasomes harboring a mixed assortment of cP and iP catalytic subunits exist in cancer cells and that their PI sensitivity differs from those of standard cP or iP5. Our results also indicated not only differing expression levels of proteasome catalytic subunits between H727 and H23 cells, but also differing levels of subunit catalytic activity. These findings are consistent with the presence of non-standard 20S proteasome subtypes (other than cP...
and iP). Determination of the 20S proteasome subtypes present in H727 cancer cells may shed further light on the underlying mechanisms of de novo Cfz resistance in H727 cells. Determination of the subunit composition of intact 20S proteasomes in cells is challenging and several groups including ours are currently trying to develop bi-functional or fluorescent probes to facilitate these efforts.\textsuperscript{30,42,43}

In summary, we show here that H727 cancer cells are intrinsically resistant to Cfz but remain dependent on the proteasome for their survival and growth. Current mechanistic studies suggest that the composition of proteasome catalytic subunits may play an important role in determining sensitivity to Cfz. Our study also implies that proteasome inhibition by alternative PIs may still be a valid therapeutic strategy for patients with relapsed MM after having received treatment with Cfz.

**Materials and Methods**

**Cell lines and chemicals.** MDA-MB-231, HCC1143, and HCC1937 breast cancer cells were purchased from the Korean Cell Line Bank (Seoul, Korea). Hep3B, Huh7, LCSC, HepG2, and PLC/PRF/5 hepatic cancer cells were a kind gift of Dr. Roberto Gedaly (College of Medicine, University of Kentucky). All other established cell lines were obtained from the American Type Culture Collection (ATCC, Rockville, MD). All cells were cultured according to the manufacturer’s protocol in 5% CO\(_2\) in medium. Cultured cell lines were tested for Mycoplasma contamination routinely every 6 months. Specifically, H23 and H727 cells were tested twice in the course of performing the experiments described within this publication (Supplementary Fig. S4). Inhibitors of UPS pathways used in this study were purchased from commercial vendors: carfilzomib (LC Laboratories, Woburn, MA), bortezomib (ChemieTek, Indianapolis, IN), MG-132 (EMD Millipore, San Diego, CA), PYR-41 (ApexBio, Houston, TX), and P5091 (ApexBio, Houston, TX). The following proteasome fluorogenic substrates were used: Suc-LILV-AMC (Bachem, Torrance, CA; I-1395), Ac-WLA-AMC (Boston Biochem, Cambridge, MA; S-330), Ac-nLPnLD-AMC (Bachem; I-1850), Ac-RLR-AMC (Boston Biochem; S-290), Ac-ANW-AMC (Boston Biochem; S-320), and Ac-PAL-AMC (Boston Biochem; S-310). Human recombinant Interferon-γ was purchased from eBioscience (San Diego, CA).

**Cell viability assay.** Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation assay (Promega, Madison, WI) according to the manufacturer's protocol. Briefly, cells were seeded at a density of 5,000–10,000 per well in 96-well plates and allowed 24 hours to attach. After cells were treated with the indicated concentrations of compounds for 72 hours, cell viability was measured using the reagent provided in the assay kit. Absorbance at 490 nm was measured using a SpectraMax M5 microplate reader ( Molecular Devices, Sunnyvale, CA). Results were analyzed using GraphPad Prism (La Jolla, CA).

**Proteasome activity profiling.** Subunit-selective fluorogenic peptide substrates were used to measure the catalytic activities of individual catalytic subunits by monitoring the rate of substrate hydrolysis over time. Briefly, protein lysates were prepared using passive lysis buffer (Promega, Madison, WI) and diluted in 20S proteasome assay buffer (20 mM Tris–HCl, 0.5 mM EDTA, 0.035% SDS, pH 8.0). Enzyme reactions were initiated by the addition of proteasome substrates. Substrates and concentrations were used as following: Suc-LILV-AMC (35/5i, 100 μM), Ac-WLA-AMC (35, 20 μM), Ac-nLPnLD-AMC (31, 100 μM), Ac-RLR-AMC (32/2i, 20 μM), Ac-ANW-AMC (35i, 100 μM), and Ac-PAL-AMC (31i activity, 100 μM). Fluorescence signals were measured over 1 hour at one reading per one minute using a SpectraMax M5 microplate reader at the excitation and emission wavelengths of 360 and 460 nm, respectively.

**Immunoblotting analysis.** Total cell lysates containing equivalent protein content were separated by 12% SDS-PAGE and transferred to polyvinylidene difluoride membranes (Millipore, Billerica, MA) via a semi-dry apparatus. membranes were then blocked in 5% non-fat dry milk (Bio-Rad, Hercules, CA) in Tris-buffered saline with 0.05% Tween-20 (TBST) for 1 h at room temperature, followed by incubation with 3% BSA in TBST containing the respective primary antibodies overnight at 4 °C: β-tubulin (Enzo Life Sciences; PW8140), β-actin (Novus Biologicals; NB600-501), and GAPDH (Santa Cruz; sc-1003). Densitometric analysis was performed using ImageJ (NIH, Bethesda, MD). Blots were incubated with secondary antibodies at 1:10,000 dilution followed by visualization using ECL Prime Western Blotting Detection Reagent (Thermo Fisher Scientific, Waltham, MA).

**IFN-γ-induced transformation of the proteasome into the immunoproteasome.** H727 and H23 cells were treated with 150 U ml\(^{-1}\) of IFN-γ or vehicle for 24 h. At the end of IFN-γ treatment, the cells were washed with PBS three times and then cultured for an additional 24 hours. Afterwards the cells were sub-cultured into a 96-well plate, and cell viability assays was performed using CellTiter 96 AQueous One Solution Cell Proliferation assay (Promega, Madison, WI) as described above. The remaining cells were then used for immunoblotting analysis and proteasome activity assays.

**Knockdown of proteasome catalytic subunits.** Cells were transfected with ON-TARGET Plus Smart Pool siRNAs (Dharmacon, Lafayette, CO) using Lipofectamine 2000 transfection reagent (Invitrogen, Carlsbad, CA), according to the manufacturer’s instructions. H727 cells were plated on 6-well plate at a density of 5 × 10\(^5\) cells per well and allowed at least 24 h to attach. Cells were then transfected with 100 nmoles of siRNAs and Lipofectamine 2000. At 4 h post-transfection, serum-free Opti-MEM medium (Invitrogen, Carlsbad, CA) was replaced with complete medium and the cells were incubated for 48 h. The following siRNA pools were used: PSMB5 (L-004522-00-0020), PSMB7 (L-006021-00-0020), PSMB8 (L-006022-00-0020), PSMB9 (L-006023-00-0005), and PSMB10 (L-006019-00-0020). For the negative control, human non-targeting scrambled siRNA (D-001810-10) was used.
Statistics. Results are expressed as means ± S.D. Statistical significance of the observed differences was determined using Student’s t-test (with the Holm-Sidak method when appropriate). All statistical analyses were carried out using GraphPad Prism 7.04 (GraphPad Software).

Collection of primary MM samples. Cryopreserved MM primary cells isolated from the bone marrow or peripheral blood of patients with no reported history of PI treatment were purchased from Convansat Biologics (Huntsville, AL) and AllCells (Alameda, CA). CD138-positive cells were isolated from patient samples immediately after thawing using human CD138 microbeads (Miltenyi Biotec), whole blood column kit (Miltenyi Biotec), MidiMACS magnetic separator (Miltenyi Biotec), and 30 μM MACS SmartStrainers (Miltenyi Biotec). Purified cells were plated on white 96-well cell culture plates at 40,000 cells per well in RPMI 1640 media supplemented with 10% FBS. Cells were treated with proteasome inhibitors for 48 hours before viability assessment via CellTiter-Glo Luminescent Cell Viability Assay (Bio-Rad).

Data Availability

The data that support the findings of this study are available from the corresponding author upon reasonable request.

References

1. Schmidt, M. & Finley, D. Regulation of proteasome activity in health and disease. Biochim Biophys Acta 1843, 13–25, https://doi.org/10.1016/j.bbcan.2013.08.012 (2014).
2. Wang, X., Zhao, Z., Iao, Y., Chen, G. & Li, Z. Gel-based proteomics analysis of the heterogeneity of 20S proteasomes from four human pancreatic cancer cell lines. Proteomics Clin Appl 5, 484–492, https://doi.org/10.1002/prca.201000149 (2011).
3. Guillaume, B. et al. Two abundant proteasome subtypes that uniquely process some antigens presented by HLA class I molecules. Proc Natl Acad Sci USA 107, 18599–18604, https://doi.org/10.1073/pnas.1009778107 (2010).
4. Dahlmann, B., Ruppert, D., Koehn, L., Merfort, S. & Kloetzel, P. M. Different proteasome subtypes in a single tissue exhibit different enzymatic properties. J Mol Biol 303, 643–653, https://doi.org/10.1006/jmbi.2000.4185 (2000).
5. Kloss, A., Meiners, S., Ludwig, A. & Dahlmann, B. Multiple cardiac proteasome subtypes differ in their susceptibility to proteasome inhibitors. Cardiovasc Res 85, 367–375, https://doi.org/10.1093/cvr/cvp217 (2010).
6. Vigneron, N. & Van den Eynde, B. J. Proteasome subtypes and the processing of tumor antigens: increasing antigenic diversity. Curr Opin Immunol 24, 84–91, https://doi.org/10.1016/j.coi.2011.12.002 (2012).
7. Zheng, J., Dasgupta, A. & Rezatofighi, G. Changes in 20S subunit composition are largely responsible for altered proteasomal activities in experimental autoimmune encephalomyelitis. J Neurochem 121, 486–494, https://doi.org/10.1111/j.1471-4159.2012.07699.x (2012).
8. Carmony, K., Lee, W. & Kim, K. B. High-Resolution Snapshots of Proteasome Inhibitors in Action Revise Inhibition Paradigms and Inspire Next-Generation Design. Chembiochem 17, 2115–2117, https://doi.org/10.1002/cbic.201600488 (2016).
9. Kisselev, A. E., van der Linden, W. A. & Overkleeft, H. S. Proteasome inhibitors: an expanding army attacking a unique target. Chem Biol 19, 99–115, https://doi.org/10.1016/j.chembiol.2012.01.003 (2012).
10. Mushtaq, A. et al. Efficacy and toxicity profile of carfilzomib based regiments for treatment of multiple myeloma: A systematic review. Crit Rev Oncol Hematol 125, 1–11, https://doi.org/10.1016/j.critrevonc.2018.02.008 (2018).
11. Siegel, D. S. et al. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood 120, 2827–2828, https://doi.org/10.1182/blood-2012-05-429394 (2012).
12. Dimopoulos, M. A. et al. Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study. Br J Haematol 177, 404–413, https://doi.org/10.1111/bjh.14549 (2017).
13. Goldschmidt, H. et al. Carfilzomib-dexamethasone versus subcutaneous or intravenous bortezomib in relapsed or refractory multiple myeloma: secondary analysis of the phase 3 ENDEAVOR study. Leuk Lymphoma, 1–11, https://doi.org/10.1080/10428194.2017.1376743 (2017).
14. Dimopoulos, M. A. et al. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial. Lancet Oncol 18, 1327–1337, https://doi.org/10.1016/S1470-2045(17)30578-8 (2017).
15. Hajek, R. et al. A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS). Leukemia 31, 107–114, https://doi.org/10.1038/leu.2016.176 (2017).
16. Berenson, J. R. et al. CHAMPION-1: a phase 1/2 study of once-weekly carfilzomib and dexamethasone for relapsed or refractory multiple myeloma. Blood 127, 3360–3368, https://doi.org/10.1182/blood-2015-11-683854 (2016).
17. Shah, C. et al. Efficacy and safety of carfilzomib in relapsed and/or refractory multiple myeloma: systematic review and meta-analysis of 14 trials. Oncotarget 9, 23704–23717, https://doi.org/10.18632/oncotarget.25281 (2018).
18. Lendvai, N. et al. A phase 2 single-center study of carfilzomib 56 mg/m² with or without low-dose dexamethasone in relapsed multiple myeloma. Blood 124, 899–906, https://doi.org/10.1182/blood-2014-02-556308 (2014).
19. Avet-Loiseau, H. et al. Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma. Blood 128, 1174–1180, https://doi.org/10.1182/blood-2016-03-707596 (2016).
20. Dimopoulos, M. A. et al. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol 17, 27–38, https://doi.org/10.1016/S1470-2045(15)00464-7 (2016).
21. Stewart, A. K. et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med 372, 142–152, https://doi.org/10.1056/NEJMoa1411323 (2015).
22. Shah, J. I. et al. Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory multiple myeloma. Blood 126, 2284–2290, https://doi.org/10.1182/blood-2015-05-643320 (2015).
23. Riz, I., Hawley, T. S. & Hawley, R. G. KLF4-SQSTM1/p62-associated prosurvival autophagy contributes to carfilzomib resistance in multiple myeloma models. Oncotarget 6, 14814–14831, https://doi.org/10.18632/oncotarget.4530 (2015).
24. Ao, L. et al. Development of peptide-based reversing agents for p-glycoprotein-mediated resistance to carfilzomib. Mol Pharmacol 9, 2197–2205, https://doi.org/10.1124/mpp.300044b (2012).
25. Zang, Y., Kirk, C. J. & Johnson, D. E. Carfilzomib and oprozomib synergize with histone deacetylase inhibitors in head and neck squamous cell carcinoma models of acquired resistance to proteasome inhibitors. Cancer Biol Ther 15, 1142–1152, https://doi.org/10.4161/cbt.29452 (2014).
26. Besse, A. et al. Carfilzomib resistance due to ABCB1/MDR1 overexpression is overcome by nelfinavir and lopinavir in multiple myeloma. Leukemia, https://doi.org/10.1038/leu.2017.212 (2017).
27. Verbrugge, S. E. et al. Inactivating PSMB5 mutations and P-glycoprotein (multidrug resistance-associated protein)–ATP-binding cassette B1) mediate resistance to proteasome inhibitors: ex vivo efficacy of (immuno)proteasome inhibitors in monoclonal blood cells from patients with rheumatoid arthritis. J Pharmacol Exp Ther 341, 174–182, https://doi.org/10.1124/jpet.117.2187542 (2012).
28. Schrader, J. et al. The inhibition mechanism of human 20S proteasomes enables next-generation inhibitor design. *Science* **353**, 594–598, https://doi.org/10.1126/science.aaf993 (2016).

29. Meng, L. et al. Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity. *Proc Natl Acad Sci USA* **96**, 10403–10408 (1999).

30. Dahiqvest, J., Torma, H., Badnai, J. & Dahl, N. siRNA silencing of proteasome maturation protein (POMP) activates the unfolded protein response and constitutes a model for KLICK genodermatosis. *PLoS One* **7**, e29471, https://doi.org/10.1371/journal. pone.0029471 (2012).

31. Murata, S., Yashiroda, H. & Tanaka, K. Molecular mechanisms of proteasome assembly. *Nat Rev Mol Cell Biol* **10**, 104–115, https://doi.org/10.1038/nrm2630 (2009).

32. Chauhan, D. et al. A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance. *Cancer Cell* **22**, 345–358, https://doi.org/10.1016/j.cccr.2012.08.007 (2012).

33. Carmony, K. C. & Kim, K. B. Activity-based imaging probes of the proteasome. *Cell Biochem Biophys* **67**, 91–101, https://doi.org/10.1007/s12013-013-9626-4 (2013).

34. Griffin, T. A. et al. Immuno-proteasome assembly: cooperative incorporation of interferon gamma (IFN-gamma)-inducible subunits. *J Exp Med* **187**, 97–104 (1998).

35. Jaitin, D. A. & Schreiber, G. Upregulation of a small subset of genes drives type I interferon-induced antiviral memory. *J Interferon Cytokine Res* **27**, 653–664, https://doi.org/10.1089/jir.2006.0162 (2007).

36. Nathan, J. A. et al. Immuno- and constitutive proteasomes do not differ in their abilities to degrade ubiquitinated proteins. *Cell* **152**, 1184–1194, https://doi.org/10.1016/j.cell.2013.01.037 (2013).

37. Dunn, G. P., Sheehan, K. C., Old, L. J. & Schreiber, R. D. IFN unresponsiveness in LNCaP cells due to the lack of JAK1 gene expression. *Cancer Res* **65**, 3447–3453, https://doi.org/10.1158/0008-5472.CAN-04-4316 (2005).

38. Richardson, P. G. et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. *N Engl J Med* **348**, 2609–2617, https://doi.org/10.1056/NEJMoa030288 (2003).

39. Oerlemans, R. et al. Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein. *Blood* **112**, 2489–2499, https://doi.org/10.1182/blood-2007-08-104950 (2008).

40. Wu, Y. X., Yang, J. H. & Saijo, H. Bortezomib-resistance is associated with increased levels of proteasome subunits and apoptosis avoidance. *Oncotarget* **7**, 77622–77634, https://doi.org/10.18632/oncotarget.12731 (2016).

41. Park, J. E. et al. An FRET-based approach for identification of proteasome catalytic subunit composition. *Nat Biotechnol* **10**, 196–200, https://doi.org/10.1038/nbt70471b (2014).

42. de Bruin, G., Xin, B. T., Florea, B. I. & Overkleeft, H. S. Proteasome Subunit Selective Activity-Based Probes Report on Proteasome Core Particle Composition in a Native Polyacrylamide Gel Electrophoresis Fluorescence-Resonance Energy Transfer Assay. *J Am Chem Soc* **138**, 9874–9880, https://doi.org/10.1021/jacs.6b04207 (2016).

**Acknowledgements**

We would like to thank the National Institutes of Health (R01 CA188354 to K.B.K.), the National R&D Program for Cancer Control, Ministry of Health and Welfare, Republic of Korea (No. 1520250 to W.L.) and Creative-Pioneering Researchers Program through Seoul National University (to W.L.) for financially supporting this work.

**Author Contributions**

K.B.K. and W.L. conceived the study, designed the experiments and wrote the paper; M.J.L., Z.M., J.P. and D.B. conducted experiments, acquired and analyzed the data. All authors discussed the results and conclusions and reviewed the manuscript.

**Additional Information**

**Supplementary information** accompanies this paper at https://doi.org/10.1038/s41598-019-40635-1.

**Competing Interests:** The authors declare no competing interests.

**Publisher's note:** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© The Author(s) 2019